Brokerages Set Alector, Inc. (NASDAQ:ALEC) Price Target at $14.50

Shares of Alector, Inc. (NASDAQ:ALEC) have earned an average rating of “Moderate Buy” from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $14.50.

Separately, HC Wainwright restated a “buy” rating and set a $41.00 price objective on shares of Alector in a report on Wednesday, February 28th.

Insider Activity at Alector

In other Alector news, CEO Arnon Rosenthal sold 18,837 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $6.92, for a total transaction of $130,352.04. Following the sale, the chief executive officer now directly owns 2,000,380 shares in the company, valued at approximately $13,842,629.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Arnon Rosenthal sold 18,837 shares of the stock in a transaction on Monday, March 4th. The shares were sold at an average price of $6.92, for a total transaction of $130,352.04. Following the completion of the sale, the chief executive officer now owns 2,000,380 shares of the company’s stock, valued at $13,842,629.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gary Romano sold 6,001 shares of the business’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $6.92, for a total transaction of $41,526.92. Following the completion of the sale, the insider now directly owns 196,313 shares in the company, valued at $1,358,485.96. The disclosure for this sale can be found here. In the last three months, insiders sold 30,554 shares of company stock worth $211,434. 14.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Vident Investment Advisory LLC boosted its position in Alector by 11.6% during the 4th quarter. Vident Investment Advisory LLC now owns 11,440 shares of the company’s stock worth $106,000 after acquiring an additional 1,188 shares during the last quarter. Diversified Trust Co boosted its holdings in Alector by 12.3% during the fourth quarter. Diversified Trust Co now owns 14,102 shares of the company’s stock worth $113,000 after purchasing an additional 1,541 shares during the last quarter. Legal & General Group Plc grew its position in Alector by 3.0% in the fourth quarter. Legal & General Group Plc now owns 53,302 shares of the company’s stock valued at $492,000 after purchasing an additional 1,554 shares in the last quarter. Rhumbline Advisers increased its stake in Alector by 2.9% in the 1st quarter. Rhumbline Advisers now owns 61,472 shares of the company’s stock valued at $876,000 after buying an additional 1,753 shares during the last quarter. Finally, Quantbot Technologies LP bought a new stake in Alector during the 1st quarter worth about $25,000. 85.83% of the stock is owned by institutional investors and hedge funds.

Alector Stock Performance

NASDAQ ALEC opened at $5.09 on Friday. Alector has a 12 month low of $3.66 and a 12 month high of $9.06. The stock has a 50-day simple moving average of $6.21 and a 200 day simple moving average of $6.21. The company has a market capitalization of $487.37 million, a PE ratio of -3.28 and a beta of 0.79.

Alector (NASDAQ:ALEC) last posted its earnings results on Tuesday, February 27th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.31. The company had revenue of $15.19 million during the quarter, compared to analyst estimates of $8.35 million. Alector had a negative return on equity of 77.15% and a negative net margin of 134.34%. As a group, sell-side analysts predict that Alector will post -1.89 earnings per share for the current fiscal year.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.